Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of bosentan in a homogeneous population of systemic sclerosis subjects with restricted hand blood flow (HOME)
2010-023908-27Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bosentan in systemic sclerosis (SSc) and digital ulcer (DU) (4 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Primary: correlation of hand blood flow with digital ulcer extent, Primary: effect of bosentan on hand blood flow at 4 weeks and 1 more. Started Nov 2010; status: completed.
02
Drugs
bosentan
03
Conditions
systemic sclerosis (SSc)digital ulcer (DU)
Beyond the preview
Go deeper on 2010-023908-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023908-27.